This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
- About the CF Foundation
- Public Policy
- Drug Pipeline
- CFTR Modulators
- Genetic Therapies
- Health Care Reform
- Clinical Trials
- Get Involved
- Our Advocacy Work
- North American CF Conference
- Cystic Fibrosis Foundation Therapeutics (CFFT)
- Care Centers
- Patient Assistance
- Infection Prevention and Control
- Patient Registry
- Coronavirus (COVID-19)
- Lung Transplantation
- In the Spotlight
- Diversity, Equity, and Inclusion
- Intro to CF
- Adult Care
- Clinician Resources
- Great Strides
- In Memoriam
- Researcher Resources
- Care Team
- CF-Related Complications
- CF Related Health Conditions
- Fertility and Reproductive Health
- (-) Our Research Approach
The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.
The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.
Potential oral formulation of drug targeting nontuberculous mycobacteria infections could reduce side effects of current treatment
Nonprofit issues challenge to accelerate treatments for every person with CF
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.